Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 23

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 23
---
 among
both stakeholders; however, price sensitivity on out-of-pocket costs was noted among both groups. Generic atovaquone-proguanil, our primary
competitor is substantially cheaper than Arakoda for the average trip length (three weeks) and has superior formulary positioning (Tier
1 vs. Tier 3). However, generic-atovaquone proguanil does not provide the same level of confidence a traveler may experience from taking
a product with a convenient weekly dosing regimen during travel, that works everywhere in the world against all malaria species and drug-resistant
strains, and which requires only a single dose for post-exposure prophylaxis upon return from a malarious area. The value those advantages
confer needs to be communicated with key stakeholders.

.
We purchased market data to understand the malaria market landscape over the past decade and identified the current prescribers of Malarone
and the generic equivalent atovaquone-proguanil, the main generic competitor to Arakoda for malaria prophylaxis. The ARAKODA commercial
pilot program commenced on March 17, 2025, with three main objectives: 1. Increase ARAKODA awareness and communicate ARAKODA’s value
proposition. 2. Drive ARAKODA trial and usage and 3. Facilitate access and affordability. The pilot includes a three-pronged approach
utilizing Virtual Sales Representatives (VSRs), a programmatic email campaign, and a co-pay offering for commercially insured patients.
We do not initially plan to target U.S. government agencies as these organizations are either contracting their ex-U.S footprints or,
as in the case of the Department of Defense, are expected to be extremely price sensitive until operational considerations justify the
use of superior products – for example, the DOD used inexpensive doxycycline for malaria prevention in the low malaria risk setting
of Afghanistan, but chose superior weekly mefloquine, despite safety concerns, for the Ebola mission to west Africa in 2014, where malaria
rates were extremely high.

<div align='center'>7</div>

Digital Revamp and Collateral:Our marketing strategy and objectives for the promotional pilot include marketing assets that we believe best highlight the features and benefits of Arakoda, namely the convenience of the travel and post-travel regimen, and global effectiveness and a co-pay benefit to reduce the out-of-pocket expense for individuals with commercial insurance. All marketing assets